Our Pricing

Compare Ozempic vs Mounjaro vs Wegovy Cost & Switch

When you compare Mounjaro vs Wegovy vs Ozempic UK cost and clinical outcomes, the differences become clear. At Cured Pharmacy, our UK-registered prescribers help patients navigate switching between GLP-1 treatments, with transparent pricing from £135.00 for Wegovy and £135.00 for Mounjaro. All three medications require clinical assessment by a UK prescriber before dispensing.

How Mounjaro, Wegovy, and Ozempic Compare Clinically

Mounjaro (tirzepatide) is the UK's first dual GIP/GLP-1 receptor agonist, activating two metabolic pathways rather than one [1]. This dual mechanism distinguishes it from Wegovy and Ozempic, both of which contain semaglutide and target only the GLP-1 receptor [2]. In head-to-head trials, tirzepatide demonstrated superior weight reduction outcomes compared to semaglutide-based treatments.

The SURPASS-2 trial showed that patients taking the 15mg Mounjaro dose achieved an average 12.4kg weight loss over 40 weeks, compared to 6.2kg with semaglutide 1mg [1]. Meanwhile, the STEP trials for Wegovy (semaglutide 2.4mg) reported average weight reductions of 14.9% over 68 weeks [2]. Ozempic, though licensed primarily for type 2 diabetes, is sometimes prescribed off-label for weight management at lower doses than Wegovy.

All three medications work by slowing gastric emptying, reducing appetite, and improving insulin sensitivity. However, their dosing schedules, side effect profiles, and clinical trial outcomes differ substantially. Your UK prescriber will assess your medical history, current medications, and weight loss goals to determine which treatment suits you best.

Mounjaro vs Wegovy vs Ozempic UK Cost Breakdown

Pricing for GLP-1 weight loss injections varies significantly across UK pharmacies, with costs influenced by dose strength, supply chain factors, and pharmacy pricing models. At Cured Pharmacy, Mounjaro starts from £135.00 and Wegovy from £135.00 with final costs determined by your prescribed dose following clinical assessment.

Ozempic is not licensed for weight management in the UK and remains primarily indicated for type 2 diabetes. While some prescribers may offer it off-label, availability remains limited due to ongoing supply constraints affecting diabetes patients who rely on it. Wegovy and Mounjaro represent the two MHRA-licensed options specifically approved for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities [3].

Transparent upfront pricing distinguishes Cured Pharmacy from providers who reveal costs only after consultation. Our prices include UK prescriber assessment, genuine UK-licensed medication, and discreet home delivery. No hidden fees, no subscription traps, no inflated 'membership' charges.

Understanding Dose Escalation Costs

Both Mounjaro and Wegovy require gradual dose escalation to minimise gastrointestinal side effects. Mounjaro typically begins at 2.5mg weekly, increasing every four weeks up to a maintenance dose of 5mg, 10mg, or 15mg depending on response and tolerability [1]. Wegovy starts at 0.25mg weekly, escalating to a maintenance dose of 2.4mg over approximately 16-20 weeks [2].

Monthly costs increase as you progress through higher dose strengths. Your UK prescriber will determine the optimal maintenance dose based on your weight loss response, side effect profile, and overall health markers. Some patients achieve their goals on lower maintenance doses, whilst others require maximum licensed doses for sustained results.

Switching from Ozempic to Mounjaro or Wegovy

Patients currently prescribed Ozempic for weight management may consider switching to Mounjaro or Wegovy for several reasons: improved weight loss outcomes, better side effect tolerance, or access to a medication specifically licensed for obesity treatment. Switching between GLP-1 medications requires careful clinical oversight to ensure safe dose conversion and minimise adverse effects.

If you're switching from Ozempic 1mg to Wegovy, your prescriber will typically restart you at Wegovy's lowest dose (0.25mg) and titrate upwards, even though both contain semaglutide [4]. This approach reduces the risk of severe nausea or vomiting during the transition. When switching from Ozempic to Mounjaro, a similar cautious escalation applies, starting at Mounjaro 2.5mg regardless of your previous Ozempic dose.

Clinical evidence suggests that patients who plateau on semaglutide-based treatments may achieve additional weight loss when switched to tirzepatide, due to its dual receptor mechanism [1]. However, switching should never be undertaken without prescriber guidance, as individual response varies and some patients experience heightened side effects during transitions.

What to Expect During the Switch

Most UK prescribers recommend a one-week washout period between stopping one GLP-1 medication and starting another, though this varies based on individual circumstances. During the switch, you may experience temporary changes in appetite, energy levels, or gastrointestinal symptoms as your body adjusts to the new medication.

Your prescriber will monitor your progress closely during the first 8-12 weeks after switching, adjusting doses based on tolerability and weight loss trajectory. Some patients notice improved outcomes within the first month, whilst others require several months to reach their previous medication's efficacy level. Patience and consistent clinical follow-up remain essential throughout the transition period.

Which Treatment Delivers the Best Weight Loss Results?

In direct comparison trials, Mounjaro (tirzepatide) has consistently demonstrated superior weight loss outcomes compared to Wegovy (semaglutide 2.4mg). The SURPASS-2 trial showed that tirzepatide 15mg produced approximately double the weight reduction of semaglutide 1mg over 40 weeks [1]. The SURMOUNT-1 trial, which enrolled participants without diabetes, reported average weight reductions of 22.5% with tirzepatide 15mg over 72 weeks [5].

Wegovy's STEP trials showed robust outcomes as well, with participants achieving average weight loss of 14.9% over 68 weeks on the 2.4mg dose [2]. These results position Wegovy as a highly effective option, particularly for patients who may not tolerate Mounjaro's dual-pathway mechanism or who respond well to semaglutide-based treatments.

Individual response varies considerably. Some patients lose substantial weight on Wegovy and experience minimal side effects, whilst others achieve better results with Mounjaro despite similar starting profiles. Factors influencing treatment response include baseline insulin resistance, genetic variations in GLP-1 receptor sensitivity, adherence to lifestyle modifications, and concurrent medications [4].

Side Effects: Mounjaro vs Wegovy vs Ozempic

All three medications share a common side effect profile dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort [1][2]. These effects typically peak during dose escalation phases and diminish as your body adapts to the medication. Approximately 30-50% of patients experience nausea during the first 8-12 weeks, though severe cases requiring discontinuation remain uncommon.

Mounjaro's dual GIP/GLP-1 mechanism may produce slightly different side effect patterns compared to semaglutide-based treatments. Some clinical observations suggest that tirzepatide causes less severe nausea in certain patients, though formal comparative data remains limited [1]. Rare but serious side effects across all three medications include pancreatitis, gallbladder disease, acute kidney injury, and hypoglycaemia (particularly in patients taking concurrent diabetes medications).

Your UK prescriber will review your complete medical history to identify contraindications before prescribing any GLP-1 treatment. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use these medications [3]. Pregnant or breastfeeding individuals must also avoid GLP-1 receptor agonists due to insufficient safety data.

Managing Side Effects Effectively

Eating smaller, more frequent meals can significantly reduce nausea and vomiting. Avoiding high-fat, spicy, or heavily processed foods during the first few weeks helps many patients tolerate dose escalations more comfortably. Staying well-hydrated and taking your injection at a consistent time each week also improves tolerability.

If side effects become severe or persistent, contact your prescriber rather than discontinuing treatment abruptly. Dose adjustments, temporary holds, or switching to an alternative medication may resolve issues whilst preserving your weight loss progress. Never adjust your dose independently without prescriber guidance.

How to Start or Switch Your Weight Loss Treatment at Cured Pharmacy

Beginning your weight loss journey or switching treatments at Cured Pharmacy takes under three minutes. Complete our free online clinical assessment, which our UK-registered prescribers review within hours. The assessment covers your medical history, current medications, weight loss goals, and any previous experience with GLP-1 treatments.

If your prescriber approves your treatment request, we'll dispense genuine UK-licensed medication and arrange discreet home delivery. Your prescription includes clear dosing instructions, injection technique guidance, and information about managing potential side effects. Our clinical team remains available for follow-up questions throughout your treatment journey.

Switching from another pharmacy or treatment is straightforward. During your assessment, inform our prescribers about your current medication, dose, and how long you've been taking it. They'll determine the safest switching protocol and starting dose for your new treatment. We'll coordinate timing to ensure you never experience a gap in your medication supply, subject to clinical appropriateness and stock availability.

Ongoing Clinical Support

Weight loss medication works best alongside sustainable lifestyle changes. Our prescribers can provide guidance on nutrition, physical activity, and behavioural strategies that complement your treatment. Regular clinical reviews help optimise your dose, monitor for side effects, and adjust your treatment plan as you progress towards your goals.

Cured Pharmacy's transparent pricing and clinical expertise have helped thousands of UK patients access effective weight management treatments. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees our clinical operations, ensuring every prescription meets the highest standards of safety and regulatory compliance.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss medications work best alongside sustainable lifestyle changes including diet and physical activity.